Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
CSL Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
CSL Ltd, Medical Devices Deals, 2012 to YTD 2018 13
CSL Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
CSL Ltd, Pharmaceuticals & Healthcare, Deal Details 19
Asset Purchase 19
CSL Acquires Influenza Vaccines Business of Novartis for USD275 Million 19
Venture Financing 23
Calimmune Raises USD15 Million in Series B Financing 23
Partnerships 24
CSL Enters into Agreement with Vitaeris 24
PaxVax Enters into Distribution Agreement with Seqirus 25
Seqirus Enters into Distribution Agreement with Valneva 26
A1M Pharma Enters into Research Agreement with CSL Behring 27
PaxVax Enters into Distribution Agreement with BioCSL 28
Alk Abello Enters into Co-Marketing Agreement with BioCSL 29
ALK-Abello Enters into Agreement with Seqirus 30
Licensing Agreements 31
Seqirus Enters into Licensing Agreement with Glenmark Specialty 31
CSL Enters into Licensing Agreement with Cevec Pharma 32
CSL Enters into Licensing Agreement with Momenta Pharma 33
Seqirus Enters into Licensing Agreement with Zambon 35
Calimmune Enters into Licensing Agreement with Cincinnati Children’s Hospital Medical Center 36
Calimmune Enters into Licensing Agreement with Asklepios BioPharma 37
Calimmune Enters into Licensing Agreement with St. Jude Children’s Research Hospital 38
BioCryst Pharma Enters into Licensing Agreement with Seqirus 39
Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 41
CSL Enters Into Licensing Agreement With Janssen For CSL-362 42
CSL Enters into Licensing Agreement with Xencor 43
Benitec Enters Into Licensing Agreement With Calimmune For ddRNAi Technology 44
Debt Offering 45
CSL Raises USD200 Million in Private Placement of 3.32% Debt Securities Due 2029 45
CSL Raises USD150 Million in Private Placement of 3.47% Debt Securities Due 2032 46
CSL Raises USD100 Million in Private Placement of 3.77% Debt Securities Due 2037 47
CSL Raises USD250 Million in Private Placement of 3.17% Debt Securities Due 2027 48
CSL Raises USD258 Million in Private Placement of 0.955% Debt Securities Due 2025 49
CSL Raises USD155 Million in Private Placement of 0.755% Debt Securities Due 2023 50
CSL Raises USD100 Million in Private Placement of 3.63% Debt Securities Due 2025 51
CSL Raises USD200.5 Million in Private Placement of 1.93% Debt Securities Due 2024 52
CSL Raises USD134 Million in Private Placement of 2.1% Debt Securities Due 2026 53
CSL Raises USD134 Million in Private Placement of 1.65% Debt Securities Due 2022 54
CSL Completes Private Placement Of Debt Securities Due 2023 For US$150 Million 55
CSL Completes Private Placement Of Debt Securities Due 2018 For US$100 Million 56
CSL Completes Private Placement Of Debt Securities Due 2020 For US$150 Million 57
CSL Completes Private Placement Of Debt Securities Due 2025 For US$100 Million 58
Asset Transactions 59
Paragon Care to Acquire Immunohaematology Business Unit from Seqirus for USD6.4 Million 59
Acquisition 60
CSL to Acquire Remaining 20% Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD102 Million 60
CSL Behring Acquires Calimmune 61
CSL Acquires 80% Equity Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD352 Million 62
CSL Ltd – Key Competitors 63
CSL Ltd – Key Employees 64
CSL Ltd – Locations And Subsidiaries 65
Head Office 65
Other Locations & Subsidiaries 65
Recent Developments 68
Strategy And Business Planning 68
Dec 07, 2017: Expansion of CSL Biotech Facility Drives Advanced Manufacturing Growth and Creates Victorian Jobs 68
Financial Announcements 69
Aug 15, 2018: CSL Delivers a Full Year Net Profit of $1.7 billion 69
Aug 16, 2017: CSL announces Full Year Result 2017 71
Feb 15, 2017: CSL Announces Half Year Result 2017 73
Jan 19, 2017: CSL reports FY2017 profit upgrade 75
Corporate Communications 76
Dec 13, 2017: CSL Appoints New Directors 76
Government and Public Interest 78
Oct 17, 2017: Australian Scientists awarded $2.5m to support ground-breaking medical research into cancer diagnostics and cardiovascular disease 78
Product News 79
09/14/2017: CSL Behring Announces FDA Approval of Privigen [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults 79
08/30/2017: Momenta Pharmaceuticals to Webcast Presentation at the 2017 Wells Fargo Healthcare Conference 80
08/09/2017: Berinert Approved by Health Canada for the Treatment of Hereditary Angioedema (HAE) in Pediatric Patients 81
07/11/2017: CSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders 82
06/15/2018: CSL Behring Presents New Data on Subcutaneous Immunoglobulin Treatment from the Largest CIDP Study, the PATH Trial, at the 4th Congress of the European Academy of Neurology 83
04/20/2018: CSL Behring, Leader in Rare Diseases, Showcases Innovations in Neuromuscular Medicine (NMM) at the 2018 American Academy of Neurology Annual Meeting 84
03/16/2018: FDA Approves Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy 85
01/26/2018: CHMP Recommends Extension of Indications for Hizentra 86
Product Approvals 87
Jul 19, 2017: FDA Accepts CSL Behrings Supplemental Biologics License Application for Hizentra Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication 87
Feb 14, 2017: FDA Accepts CSL Behring’s Biologics License Application Supplement for Using Privigen to Treat Chronic Inflammatory Demyelinating Polyneuropathy, a Rare Neurological Condition 88
Clinical Trials 89
Oct 03, 2018: Seqirus presents favorable outcomes data for adjuvanted trivalent influenza vaccine (FLUAD) at 6th Annual IDWeek 89
Nov 09, 2017: Lancet Neurology Publishes Results from CSL Behring Phase III Study of Hizentra (Immune Globulin Subcutaneous [Human] 20% liquid) as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy 91
Apr 04, 2017: New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring’s Subcutaneous C1-Esterase Inhibitor in HAE Patients 92
Mar 22, 2017: NEJM Publishes Pivotal Data on Preventing HAE Attacks 93
Mar 01, 2017: CSL Behring Announces Largest Ever CIDP Clinical Study Completed 94
Appendix 95
Methodology 95
About GlobalData 95
Contact Us 95
Disclaimer 95
CSL Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
CSL Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
CSL Ltd, Deals By Therapy Area, 2012 to YTD 2018 11
CSL Ltd, Medical Devices Deals, 2012 to YTD 2018 13
CSL Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
CSL Acquires Influenza Vaccines Business of Novartis for USD275 Million 19
Calimmune Raises USD15 Million in Series B Financing 23
CSL Enters into Agreement with Vitaeris 24
PaxVax Enters into Distribution Agreement with Seqirus 25
Seqirus Enters into Distribution Agreement with Valneva 26
A1M Pharma Enters into Research Agreement with CSL Behring 27
PaxVax Enters into Distribution Agreement with BioCSL 28
Alk Abello Enters into Co-Marketing Agreement with BioCSL 29
ALK-Abello Enters into Agreement with Seqirus 30
Seqirus Enters into Licensing Agreement with Glenmark Specialty 31
CSL Enters into Licensing Agreement with Cevec Pharma 32
CSL Enters into Licensing Agreement with Momenta Pharma 33
Seqirus Enters into Licensing Agreement with Zambon 35
Calimmune Enters into Licensing Agreement with Cincinnati Children’s Hospital Medical Center 36
Calimmune Enters into Licensing Agreement with Asklepios BioPharma 37
Calimmune Enters into Licensing Agreement with St. Jude Children’s Research Hospital 38
BioCryst Pharma Enters into Licensing Agreement with Seqirus 39
Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 41
CSL Enters Into Licensing Agreement With Janssen For CSL-362 42
CSL Enters into Licensing Agreement with Xencor 43
Benitec Enters Into Licensing Agreement With Calimmune For ddRNAi Technology 44
CSL Raises USD200 Million in Private Placement of 3.32% Debt Securities Due 2029 45
CSL Raises USD150 Million in Private Placement of 3.47% Debt Securities Due 2032 46
CSL Raises USD100 Million in Private Placement of 3.77% Debt Securities Due 2037 47
CSL Raises USD250 Million in Private Placement of 3.17% Debt Securities Due 2027 48
CSL Raises USD258 Million in Private Placement of 0.955% Debt Securities Due 2025 49
CSL Raises USD155 Million in Private Placement of 0.755% Debt Securities Due 2023 50
CSL Raises USD100 Million in Private Placement of 3.63% Debt Securities Due 2025 51
CSL Raises USD200.5 Million in Private Placement of 1.93% Debt Securities Due 2024 52
CSL Raises USD134 Million in Private Placement of 2.1% Debt Securities Due 2026 53
CSL Raises USD134 Million in Private Placement of 1.65% Debt Securities Due 2022 54
CSL Completes Private Placement Of Debt Securities Due 2023 For US$150 Million 55
CSL Completes Private Placement Of Debt Securities Due 2018 For US$100 Million 56
CSL Completes Private Placement Of Debt Securities Due 2020 For US$150 Million 57
CSL Completes Private Placement Of Debt Securities Due 2025 For US$100 Million 58
Paragon Care to Acquire Immunohaematology Business Unit from Seqirus for USD6.4 Million 59
CSL to Acquire Remaining 20% Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD102 Million 60
CSL Behring Acquires Calimmune 61
CSL Acquires 80% Equity Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD352 Million 62
CSL Ltd, Key Competitors 63
CSL Ltd, Key Employees 64
CSL Ltd, Other Locations 65
CSL Ltd, Subsidiaries 65
List of Figures
CSL Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
CSL Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
CSL Ltd, Medical Devices Deals, 2012 to YTD 2018 13